Anti-SARS-CoV-2 Nucleocapsid (N)

Antibody Details

Product Details

Reactivity Species

SARS-CoV-2

⋅

Virus

Expression Host

HEK-293

Immunogen

Recombinant nucleoprotein of SARS-CoV (severe acute respiratory syndrome)

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

Formulation

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.

Storage and Handling

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

Ships Overnight on Blue Ice

RRID

AB_2893978

Applications and Recommended Usage?
Quality Tested by Leinco

ELISA

IHC

WB

Other Applications Reported In Literature ?

FC

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Anti-SARS-CoV-2 Nucleocapsid, clone 1C7C7, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein.

Antigen Distribution

The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family ¹. The SARS-CoV-2 genome, which shares 79.6% identity with SARS-CoV, encodes four essential structural proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid protein (N) ². The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in RNA binding and self-oligomerization, respectively ^{3, 4}. The primary function of the N protein is to bind to and package the viral RNA genome into a helical ribonucleoprotein complex ⁵. The N protein is also involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways ^{6, 7}. The N protein is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein ⁸. It is also immunogenic, and antibodies ^{8, 9} and memory T cells ^{10, 11} targeting the N protein are present in the sera of convalescent COVID-19 patients, identifying the N protein as a suitable candidate for vaccine development and diagnostic assays. Diagnostic assays based on the N protein effectively detect antibodies in the sera of patients infected with SARS-CoV-2 ¹². The N protein also contributes to immune evasion by antagonizing antiviral RNAi ¹³, suggesting its potential value as a targeted therapeutic.

Antigen Details

Protein

SARS-CoV-2 Nucleocapsid (N)

PubMed

SARS-CoV-2 Nucleocapsid (N)

NCBI Gene Bank ID

43740575

Research Area

COVID-19

.

Viral

References & Citations

1.Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.

2.Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.

3.Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.

4.Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.

5.Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.

6.Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.

7.Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.

8.Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.

9.To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.

11.Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.

12.Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.

13.Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.

Technical Protocols